Drug-Like Antibodies Straight from Selections

Specialists in the creation of exceptional Antibody Libraries

Find Out More

Why Choose The Specifica Platform?

With visionary antibody technologies and deal structures to match, we are focused on empowering you to generate antibody drugs against any target, to create cures for any disease.

Find out more about our mission

Drug-like antibodies

Antibodies selected from our libraries have high affinities and developability properties, as good as, or better, than clinical antibodies on the market, saving you time and money during development.

Affinity

60% of antibodies selected directly from our Generation 3 libraries have affinities below 10nM; 20% have affinities in the subnanomolar range; and our best affinity antibody to date is 13 pM

Diversity

After selection we use the machine learning module of AbXtract to group selected antibodies into as many as 1,000 distinctive clusters, providing antibodies against a wide variety of target epitopes.

Developability

Over 80% of antibodies from our Generation 3 Platform have no measurable biophysical liabilities, with all tested to date behaving as well as, or better, than the best therapeutic antibodies.

Full platform transfer

To empower discovery at your site, we equip you with our integrated, state-of-the-art, antibody discovery platform, including exclusive libraries, vectors, protocols and extensive training.

Exclusive assets

All our libraries are provided as exclusive assets, with HCDR3 donors used once and other CDRs reassembled for each library, making the antibody diversity yours alone to mine, and not shared with others.

Collaborate & customize

In addition to in-house designs, we create custom libraries, modifying scaffolds, tags, vectors or excluded liabilities. When you need more hands, let us conduct discovery using your exclusive library.

Antibody discovery

We use our in-house libraries, integrated selection pipeline, next generation sequencing and AbXtract to generate unusually diverse, high affinity, drug-like, developable antibodies.

Straightforward terms

Our terms eliminate complexities typically seen in platform transfers. We recognize each company is unique, and have successfully tailored structures to meet each partner’s needs.

Find out more about

what we do

Discover our Antibody Libraries and what makes us different.

What We Do

Our team of highly collaborative, creative, hard-working professionals.

Meet The Team